www.astro.org
Abstract # 1023 Improved Disease Specific and Overall Survival in Patients with Early Stage Low Grade Follicular Lymphoma Treated with External Beam Radiation: A Surveillance, Epidemiology, and End Results Analysis

Presenter: Pugh, Thomas

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos


Results:
6581 patients were identified forming the study cohort. Median follow up was 66 months(m) (range 3‐360m). Demographic and clinical characteristics were as follows: 58% ≥ 60 years (y) old (median age = 62 y), 52% male, 93% white, 67% stage I, 33% stage II, 60% no E, 17% E, and 23% E not coded. Only 34% of pts (n=2228) were treated with EBRT. Utilization of EBRT was increased in younger (39% for <60; 31% for >60) and earlier stage (39% for stage I; 24% for stage II) pts. EBRT improved actuarial DSS with values at 5, 10, 15, and 20 years in the EBRT group of 90%, 79%, 70%, 65% vs 82%, 66%, 58% ,52% in the no EBRT group (HR 0.59 95% CI 0.53‐0.66 p<0.0001). EBRT also improved actuarial OS at 5, 10, 15, and 20 years with values of 81%, 62%, 45%, 35% vs 71%, 48%, 34%, 23% in patients not receiving EBRT (HR 0.67 95% CI 0.63‐0.73 p<0.0001). Median DSS for stage I and stage II pts without EBRT was 23.3 y and 23.5 y. Median DSS was not reached in pts receiving EBRT. Median OS by stage and treatment were as follows: stage I EBRT 14.3y, stage I No EBRT 9.8y, stage II EBRT 10.8y , stage II No EBRT 8.8 y. Ten year DSS was improved for stage I (81%) vs stage II (73%) pts treated with EBRT (p<0.001). On multivariate analysis age < 60 (HR 0.47), EBRT (HR 0.63), and Stage I (0.72) were associated with improved DSS, while age < 60 (HR 0.35), EBRT (HR 0.73), Stage I (0.81), and female gender (HR 0.88) were associate with improved OS. The percentage of pts receiving EBRT decreased with time: 1973‐79 = 41%, 1980‐1984 = 32%, 1985‐1989 = 35%, 1990‐94 = 35%, 1995‐99 = 35%, 2000‐04 = 31%.


Click on images to enlarge (a new pop-up window will open)